Development cooperation

Gavi, The Vaccine Alliance; COVAX AMC

Description

Gavi, the Vaccine Alliance promotes global immunisation against epidemics and helps vaccinate children against life-threatening infectious diseases. Gavi’s main mission is to save lives and protect the world against the threat of epidemics by promoting equitable uptake and coverage of vaccines in the poorest countries. Due to its unique business model and partnerships, it has the power to negotiate better prices for the world's poorest countries and remove the commercial risks that manufacturers faced in serving this market. Gavi plays a critical role in strengthening primary health care (PHC), bringing us closer to the Sustainable Development Goal 3 of Universal Health Coverage (UHC), ensuring that no one is left behind. Gavi plays an important role also in the global COVID-19 response. Together with the Coalition for Epidemic Preparedness Innovations (CEPI) and World Health Organization (WHO) Gavi is also co-leading COVAX Facility (COVAX). Funding of COVAX is managed through Gavi. COVAX is leading efforts to secure fair and equitable access to safe and effective COVID-19 vaccines globally and is also a central instrument for EU's global vaccine solidarity. The contribution is directed to COVID-19 Vaccines Advance Market Commitment (COVAX AMC), which is governed by Gavi. The Gavi COVAX AMC is the financing instrument that supports the participation of 92 low- and middle-income economies, inlucing the Least Developed Countries, in the COVAX Facility. This enables access to donor-funded doses of safe and effective COVID-19 vaccines and promotes the achievement of the sustainable development goals.

More information

http://www.gavi.org(layout.types.url.description)

Funding decision

2 000 000 €

Objectives monitored by OECD's Development Assistance Committee

  • Participatory development/Good governance
  • Gender equality

Field of activity

  • COVID-19 control 100%

Funding channel

The Gavi Alliance

Contact

keo-90

Code for the object of funding

89893034

ID

UHA2022-001607

Modified

30.05.2022